Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens

TW202635727APending Publication Date: 2026-09-01JANUX THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114141917
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-01
Filing Date
2025-10-29
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074533_001
    Figure TWG2TA001074533_001
  • Figure TWG2TA001074533_002
    Figure TWG2TA001074533_002
  • Figure TWG2TA001074533_003
    Figure TWG2TA001074533_003
Patent Text Reader

Abstract

Disclosed herein are isolated polypeptide and polypeptide complexes that comprise a first antigen recognizing molecule that binds to an effector cell antigen and a second antigen recognizing molecule that binds to prostate-specific membrane antigen (PSMA), wherein the second antigen recognizing molecule is linked to a peptide that impairs binding of the second antigen recognizing molecule to PSMA.
Need to check novelty before this filing date? Find Prior Art